[Two cases of recurrent breast carcinoma achieving CR (complete response) with KM2210]

Two cases of recurrent breast carcinoma were treated with KM2210 in an early phase II study conducted at our institute and complete response (CR) was obtained. Case 1, a 64-year-old woman, developed a reddish tumor at the mastectomy wound 3 years after the first operation. Two hundred milligrams of KM2210 per day was given p.o. and the tumor diminished completely within 4 wk after the initial treatment. This CR state has continued for 2 years and 4 months until the present time. Although leukopenia of less than 3,000/mm3 was observed several times during the treatment, counts of white cells recovered after the dose of KM2210 had been reduced. Case 2, a 61-year-old woman, noticed swelling of the left supraclavicular lymphnodes, one of which was confirmed to be metastatic duct cell carcinoma histologically 4 years after standard radical mastectomy. The residual two lymphnodes returned completely to normal within 4 wk after the initial administration of KM2210 at a dose of 100 mg/day p.o. This CR continued for 9 months until a new lesion was found in the same region. No adverse effects of the regimen were observed in this case. As KM2210 was shown to produce two CR cases in this early phase II study against recurrent breast carcinoma with few adverse effects, the further clinical application of this agent against breast carcinoma should be investigated.